A panel of internists and nephrologists developed this practical approach for the Kidney Disease Outcomes Quality Initiative to guide assessment and care of chronic kidney disease (CKD) by primary care clinicians. Chronic kidney disease is defined as a glomerular filtration rate (GFR) <60 mL/min/1.73 m 2 and/or markers of kidney damage for at least 3 months. In clinical practice the most common tests for CKD include GFR estimated from the serum creatinine concentration (eGFR) and albuminuria from the urinary albumin-tocreatinine ratio. Assessment of eGFR and albuminuria should be performed for persons with diabetes and/or hypertension but is not recommended for the general population. Management of CKD includes reducing the patient's risk of CKD progression and risk of associated complications, such as acute kidney injury and cardiovascular disease, anemia, and metabolic acidosis, as well as mineral and bone disorder. Prevention of CKD progression requires blood pressure <140/90 mm Hg, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for patients with albuminuria and hypertension, hemoglobin A1c S7% for patients with diabetes, and correction of CKD-associated metabolic acidosis. To reduce patient safety hazards from medications, the level of eGFR should be considered when prescribing, and nephrotoxins should be avoided, such as nonsteroidal anti-inflammatory drugs. The main reasons to refer to nephrology specialists are eGFR <30 mL/min/1.73 m 2 , severe albuminuria, and acute kidney injury. The ultimate goal of CKD management is to prevent disease progression, minimize complications, and promote quality of life.
New data from 50 cohorts totaling more than 2 million individuals has demonstrated a strong and linear increase in the risk of adverse outcomes for chronic kidney disease according to the 2002 definition of an estimated glomerular filtration rate <60 mL/min/1.73 m 2 or albumin-to-creatinine ratio >30 mg/g (>3 mg/mmol). 3 In 2012 the Kidney Disease Improving Global Outcomes released a new guideline for chronic kidney disease that adds refinements based on cause, estimated glomerular filtration rate, and albuminuria categories (see Appendix A [available online] for guideline statements). 4 Consideration of the cause of chronic kidney disease fundamentally affects management by distinguishing a systemic condition from one that is localized to the kidney, such as a glomerular disease. The albuminuria is complementary to low estimated glomerular filtration rate because both independently influence prognosis, as demonstrated by a heat map of the new classification illustrating an increasing risk of chronic kidney disease progression, morbidity, and mortality ( Figure 1) . 4 This new grid offers a practical guide for primary care clinicians to inform monitoring and management of chronic kidney disease.
The estimated prevalence of chronic kidney disease in the general population exceeds 10%, 3, 5 outstripping the availability of nephology specialists and requiring primary care clinicians to care for the majority of these patients. A panel of internists and nephrologists developed this practical approach to guide assessment and care of chronic kidney disease by primary care clinicians, described in the following sections on detection, progression, patient safety, interaction with cardiovascular disease, and nephrology referral.
TOPIC 1: DETECTION OF CHRONIC KIDNEY DISEASE Overview
Expert panels have identified insufficient evidence to support general population-based testing for chronic kidney disease.
1,4,6-9 Both the Kidney Disease Outcomes Quality Initiative and the Kidney Disease Improving Global Outcomes chronic kidney disease guidelines have recommended targeted testing for chronic kidney disease among high-risk populations with diabetes and/or hypertension. 1, 4, 9 In practice, detection of chronic kidney disease often occurs during routine care because serum creatinine testing is included in ubiquitous basic and comprehensive metabolic panels. Early detection of chronic kidney disease offers a valuate opportunity to avert complications before symptoms occur and to slow loss of kidney function over time. [10] [11] [12] [13] [14] [15] [16] Compared with persons whose chronic kidney disease remains undetected, those with chronic kidney disease diagnosed by a primary care clinician are more likely to avoid risky use of nonsteroidal antiinflammatory drugs (NSAIDs) 17 ; use angiotensin-converting-enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) when indicated 17, 18 ; and receive appropriate nephrology care. 18 
Kidney Function: Estimated Glomerular Filtration Rate
Detection of chronic kidney disease based on estimated glomerular filtration rate is a more accurate assessment of kidney function than serum creatinine alone. 1, 4, 9 Two equations are used in practice to estimate glomerular filtration rate, the Chronic Kidney DiseaseeEpidemiology Collaboration equation and the older Modification of Diet in Renal Disease Study equation. Recent studies have found that the Chronic Kidney DiseaseeEpidemiology Collaboration equation more accurately predicts prognosis and is less biased than the older Modification of Diet in Renal Disease Study equation. 4, 9, 19 One caveat is that any estimated glomerular filtration rate equation is inaccurate in the setting of acute kidney injury because kidney function is not in a steady state.
Urine Studies to Evaluate for Albuminuria or Proteinuria
Although quantification of albuminuria has been less widely adopted in clinical practice than assessment of estimated glomerular filtration rate, 5 it is crucial to evaluating prognosis. A spot albumin-to-creatinine ratio is a more sensitive and specific marker of chronic kidney disease than a spot urine protein/creatinine ratio, although both are predictive of clinical outcomes. 9 Standardization of urine albumin measurement is ongoing but superior to urine protein that has much wider variability. 9 A random or spot urine specimen quantifies albumin as milligrams per gram of creatinine (mg/g) ( Figure 1 ). 4 
CLINICAL SIGNIFICANCE
• Chronic kidney disease (CKD) is defined by estimated glomerular filtration rate (eGFR) and urinary albumin/creatinine ratio.
• The 4 interventions that reduce CKD progression are blood pressure control <140/90 mm Hg, use of angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for albuminuria and hypertension, diabetes control, and correction of metabolic acidosis.
• A patient safety approach to CKD considers the level of eGFR in prescription practice.
• Statin-based therapies reduce vascular events in CKD.
• Nephrology referral for advanced CKD is associated with improved outcomes. Figure 1 Risk of chronic kidney disease progression, frequency of visits, and referral to nephrology according to estimated glomerular filtration rate (eGFR) and albuminuria. The GFR and albuminuria grid depict the risk of progression, morbidity, and mortality by color, from best to worst (green, yellow, orange, red, deep red). The numbers in the boxes are a guide to the frequency of visits (number of times per year). Green can reflect CKD with normal eGFR and albumin-to-creatinine ratio (ACR) only in the presence of other markers of kidney damage, such as imaging showing polycystic kidney disease or kidney biopsy abnormalities, with follow-up measurements annually; yellow requires caution and measurements at least once per year; orange requires measurements twice per year; red requires measurements at 3 and deep red 4 times per year. These are general parameters only, based on expert opinion and must take into account underlying comorbid conditions and disease state, as well as the likelihood of impacting a change in management for any individual patient. "Refer" indicates nephrology services are recommended. *Referring clinicians may wish to discuss with their nephrology service, depending on local arrangements regarding treating or referring. This figure is adapted with permission from reference 4.
Cause of Chronic Kidney Disease: Other Tests
Evaluation with imaging or serologic testing to identify the cause of chronic kidney disease is not routinely required, 20 particularly in the presence of diabetes or hypertension. Kidney and bladder ultrasound should be performed when there is a history of urinary tract stones or obstruction, frequent urinary tract infections, or a family history of polycystic kidney disease. 1 Serologic workup is only required when a systemic or glomerular disease is suspected, such as myeloma or amyloidosis. Consider nephrology referral when the cause of kidney disease is not apparent, particularly for patients without diabetes and hypertension.
TOPIC 2: CHRONIC KIDNEY DISEASE PROGRESSION AND COMPLICATIONS

Overview
The treatment of chronic kidney disease aims to delay progressive loss of kidney function and prevent or manage complications. Four interventions clearly delay chronic kidney disease progression, including management of hypertension; use of a renin angiotensin aldosterone system (RAAS) blocker, an ACE-I, or ARB for hypertension and albuminuria; control of diabetes; and correction of metabolic acidosis. Management to delay progression and treat chronic kidney disease complications is discussed in the following sections.
Hypertension Management
For the past 10 years, the Joint National Committee on hypertension (JNC) has recommended an office blood pressure target of 130/80 mm Hg or less for patients with chronic kidney disease. 21 Recently, JNC 8 has loosened this target to S140/90 mm Hg, the same as for the general population under 60 years of age. 22 This new recommendation reflects the lack of robust data supporting a lower blood pressure target. Accordingly, recent clinical practice guidelines for blood pressure management in chronic kidney disease have suggested that a target of S130/80 mm Hg should be sought only in the context of severe albuminuria, but the evidence for this goal is of very low quality. 23 Sodium consumption is an important consideration for blood pressure control in chronic kidney disease. A diet high in sodium is a cause of resistance to hypertension medications, especially for patients with chronic kidney disease. The average American consumes more than 3500 mg sodium daily. 24 For patients with chronic kidney disease current guidelines recommend less than 2000 mg of sodium per day; however, there is lowquality evidence for this recommendation. 4, 9, [23] [24] [25] 
ACE-I or ARB
Treatment with ACE-I or ARB for hypertension in persons with chronic kidney disease with or without diabetes who have A2 and A3 levels of albuminuria is supported by low-to high-level evidence, respectively. 23 Although JNC 8 recommends a RAAS blocker for all patients with chronic kidney disease, 22 current evidence supports this treatment primarily for patients with albuminuria. Some chronic kidney disease patients can develop hyperkalemia or a decreased estimated glomerular filtration rate after starting an ACE-I or an ARB. Monitoring should include assessment of serum potassium and estimated glomerular filtration rate approximately within several weeks after initiation or dose escalation. When hyperkalemia develops, outpatient management strategies include identification and restriction of dietary potassium, treatment of metabolic acidosis if appropriate (see below), consideration of thiazide or loop diuretic use to increase potassium excretion, and treatment with a potassium-binding exchange resin. Discontinuation of the RAAS blocker should be considered only if these interventions fail. When the esti-
Glycemic Control
According to recent data regarding harms from overly intensive glycemic control, a target hemoglobin A1c (HbA1c) of approximately 7% has been recommended, with a higher target for those with a limited life expectancy or an elevated risk of hypoglycemia. 9, 28 In addition to cardiovascular risk reduction, the benefits of glycemic control in chronic kidney disease include reduced progression of albuminuria and reduced loss of kidney function over time. 14, 16, 28 Chronic Kidney Disease Anemia Measurement of hemoglobin (Hb) at least annually is recommended beginning with stage G3a chronic kidney disease, because erythropoietin production decreases with low glomerular filtration rate.
4,9 Figure 2 shows a summary of chronic kidney disease anemia management. 29 
Chronic Kidney Disease Mineral and Bone Disorder
Secondary hyperparathyroidism, hypocalcemia, hyperphosphatemia, decreased vitamin D, and vascular calcification typically begin in stage G3b, when serum calcium, phosphorus, intact parathyroid hormone, and total 25-hydroxy vitamin D should be measured at least once to document baseline levels. Figure 2 provides details on management.
30,31
Chronic Kidney Disease Metabolic Acidosis Treatment of chronic kidney diseaseeassociated metabolic acidosis with oral alkali to achieve a normal serum bicarbonate level has been shown in observational studies to slow [32] [33] [34] mated glomerular filtration rate decreases more than 25% chronic kidney disease progression. When the bicarwithin 3 months of RAAS initiation, the patient deserves additional investigation for overdiuresis or renal artery stenosis.
Dual RAAS Blockade
Combination therapy with an ACE-I plus an ARB should not be used for patients with chronic kidney disease and hypertension regardless of whether they have diabetes. Trials have shown greater complications, such as acute kidney injury and severe hyperkalemia, and no mortality or cardiovascular benefits with combination versus single-agent therapy.
26,27
Diuretic Therapy
Diuretics are generally necessary to manage extracellular fluid volume expansion and blood pressure control in chronic kidney disease. Thiazides are used especially for patients with stages G1-3b chronic kidney disease. A second-line option is a loop diuretic when the thiazide does not achieve volume control goals. Most patients with stage G4 chronic kidney disease will require a loop diuretic, and furosemide, the most common drug, should be dosed twice daily for effective diuresis. • Assess GFR and serum potassium 1-2 weeks after starting or escalating dose • Consider temporarily holding during IV contrast administration, or any potential cause of volume depletion (bowel preparation prior to colonoscopy, acute illness, and surgery) • Dose reduction/increased toxicity for GFR <30 mL/min/1.73 m 2 for lovastatin, pravastatin, and rosuvastatin Fenofibrate
• Associated with elevations in serum creatinine without a true change in GFR with an estimated glomerular filtration rate <60 mL/min/1.73 m 2 . Furthermore, they should be used with extreme caution in patients with chronic kidney disease and concomitant RAAS blocking agents and/or diuretic therapy.
4,9
Metformin
Although the US Food and Drug Administration has a blackbox warning for metformin use in patients with serum creatinine 2"1.5 mg/dL in men and 2"1.4 mg/dL in women owing to an increased risk for lactic acidosis, it is now recognized that this risk is extremely low. 38, 39 Many practice guidelines recommend discontinuing metformin use only when the estimated glomerular filtration rate is <30 mL/min/1.73 m 2 , and use with caution for patients with an estimated glomerular filtration rate of 30-45 mL/min/1.73 m 2 .
4,9,28
Iodinated Contrast
The major risk factor for contrast-induced nephropathy is chronic kidney disease. Use of N-acetylcysteine to prevent contrast-induced acute kidney injury is not consistently , confirm correct dosing because recommended dose varies by indication and level of kidney function. Additionally, assess for potential drug interactions for inhibitors or inducers of CYP34A and P-gp metabolism. Note that if there are bleeding complications, the anticoagulant effects of these agents are more difficult to reverse compared with warfarin.
• Suggested doses for nonvalvular atrial fibrillation follow:
Apixiban supported by clinical trial results, although the oral formulation has little risk. 40 Other preventive strategies include minimizing the dose of contrast, volume expansion with intravenous isotonic saline or bicarbonate, and consideration of holding medications that increase risk of acute kidney injury or complications (eg, NSAIDs, diuretics, RAAS blockers, metformin). 4, 9, 40 Most studies suggest hydration with isotonic fluids at a rate of 1 mL/kg/h, ideally started at least 1 hour before the procedure and continued for 3-6 hours afterwards. 40 The kidney function should be measured 48-96 hours after exposure during the peak in the incidence of contrast-induced acute kidney injury.
TOPIC 4: CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASE Overview
All people with chronic kidney disease should be considered at increased risk for cardiovascular disease. 1, 4, 9 In addition to well-known Framingham risk factors for cardiovascular disease, low estimated glomerular filtration rate and albuminuria have been reported to be independently predictive of cardiovascular disease and cardiovascular disease mortality in prospective cohort studies (Figure 1) . 4 Other chronic kidney diseaseespecific risk factors (anemia, mineral and bone Guidelines for lipid management in adults no longer mandate treating to a low-density lipoprotein cholesterol (LDL-C) target warrant lipid-lowering therapy and initiate when indicated; and (3) do not remeasure LDL-C unless results would alter management. 41 This last step has been particularly controversial. Measuring a lipid profile 6-12 weeks after initiating statins might be useful to ensure that an adequate (2"30%) decline in LDL-C is observed, and poor adherence or inadequate response should be considered if this goal is not achieved. 41 Many believe that continued periodic monitoring is necessary to assess ongoing adherence and for lipid alterations associated with chronic kidney disease progression. 41 
Antiplatelet Agents in Chronic Kidney Disease
Adults with chronic kidney disease should be advised to take low-dose aspirin for secondary prevention of cardiovascular disease unless the risk of bleeding outweighs the benefits. 4, 9 Unlike NSAIDs, low-dose aspirin is not associated with acute kidney injury or rapid chronic kidney disease progression. 44 
TOPIC 5: REFERRAL TO NEPHROLOGISTS Overview
Primary care clinicians play a central role in referral to specialists and care coordination for patients with chronic kidney disease. Timely referral to subspecialty care affords sufficient time to plan and prepare patients for kidney replacement therapy, as well as allowing for coordination of interventions to prevent chronic kidney disease progression and management of chronic kidney disease complications. Timely referral has been consistently shown to improve preparation for kidney replacement therapy, lower use of hemodialysis catheters and emergent hemodialysis, and increase use of transplantation and self-care dialysis (peritoneal dialysis and home hemodialysis). [45] [46] [47] [48] Studies also suggest that timely referral improves outcomes, including clinical status at kidney replacement initiation; improved management of chronic kidney diseaseerelated comorbid- 45 of 70 or 100 mg/dL, because it has not been shown to be ities; and improved survival. In most cases the primary beneficial in clinical trials. 41 Randomized controlled trials of fixed-dose statin-based therapies in chronic kidney disease have shown a reduced risk of primary and secondary atherosclerotic events, but no benefit has been demonstrated for allcause mortality or slower progression of chronic kidney disease. 41, 42 Lipid-lowering therapy in persons with chronic kidney disease who are aged 2"50 years should be based on assessing cardiovascular disease risk instead of an elevated LDL-C level. 41 Among adults with chronic kidney disease aged 18-49 years, treatment with lipid-lowering therapy is indicated for those with known coronary disease (myocardial infarction or coronary revascularization); diabetes mellitus; prior ischemic stroke; or an estimated 10-year risk of coronary death or nonfatal myocardial infarction greater than 10%. 41, 43 The currently recommended "fire and forget" strategy involves the following steps: (1) exclude remediable causes of secondary dyslipidemia (eg, nephrotic syndrome, hypothyroidism, and certain drugs); (2) assess for risk factors that care practitioner should continue to share care with the specialist because they provide complementary services.
Nephrology Referral Recommendations
Indications for nephrology referral are shown in Table 2 . The primary care clinician may choose not to refer many patients with severe albuminuria, especially those who have a clear etiology, such as diabetes. For those categories marked with an asterisk in Figure 1 , clinicians may wish to review the need to refer with a nephrology consultant on the basis of availability and the clinical context.
Conservative management without kidney replacement therapy may be appropriate for patients with stage G4 and G5 chronic kidney disease and limited life expectancy or conditions such as advanced dementia, where the burden of dialysis may outweigh its benefits. Conservative management involves medical therapy as well as treating patient symptoms (eg, pruritis, pain) and psychosocial needs CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular filtration rate.
*If this is a stable isolated finding, formal referral (ie, formal consultation and ongoing care management) may not be necessary, and advice from specialist services may be all that is required to facilitate best care for the patients. This will be healthcare system dependent.
†Progression of CKD is defined as 1 or more of the following: (1) a decline in GFR category accompanied by a 2"25% drop in eGFR from baseline; and/or (2) rapid progression of CKD, defined as a sustained decline in eGFR of more than 5 mL/min/1.73 m 2 /y. ‡Significant albuminuria is defined as albumin-to-creatinine ratio 2"300 mg/g (2"30 mg/mmol) or albumin excretion rate 2"300 mg/24 h, approximately equivalent to protein-to-creatinine ratio 2"500 mg/g (2"50 mg/mmol) or protein excretion rate 2"500 mg/24 h. This table is adapted from reference 4. 49 These patients should be managed conservatively by avoiding use of RAAS blockers 50 and limiting NSAID and contrast exposures. Last, elderly with laboratory evidence of stage G3a chronic kidney disease should be monitored closely for acute kidney injury after major surgical procedures, particularly cardiac surgery. 51 
CONCLUSION
Diabetes and hypertension present the dominant risk factors for chronic kidney disease. Testing, risk stratification, and treatment plans differ according to estimated glomerular filtration rate and urinary albumin/creatinine ratio. The major approaches to chronic kidney disease therapy include avoidance of exacerbating drugs, tests and interventions, and expectant treatment of chronic kidney disease to slow progression and reduce complications, including cardiovascular disease. A practical approach to detection and management of chronic kidney disease is provided in Figure 2 . • use a GFR estimating equation to derive GFR from serum creatinine (eGFRcreat) rather than relying on the serum creatinine concentration alone.
SUPPLEMENTAL DATA
• understand clinical settings in which eGFRcreat is less accurate.
1.4.3.4
: We recommend that clinical laboratories should (1B):
• measure serum creatinine using a specific assay with calibration traceable to the international standard reference materials and minimal bias compared with isotopedilution mass spectrometry reference methodology.
• report eGFRcreat in addition to the serum creatinine concentration in adults and specify the equation used whenever reporting eGFRcreat.
• report eGFRcreat in adults using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. An alternative creatinine-based GFR estimating equation is acceptable if it has been shown to improve accuracy of GFR estimates compared with the 2009 CKD-EPI creatinine equation.
When reporting serum creatinine:
• We recommend that serum creatinine concentration be reported and rounded to the nearest whole number when expressed as standard international units (mmol/L) and rounded to the nearest 100th of a whole number when expressed as conventional units (mg/dL). Evaluation of CKD.
1.4.1: Evaluation of chronicity
When reporting eGFR creat :
1.4.1.1: In people with GFR <60 mL/min/1.73 m 2 (GFR categories G3a-G5) or markers of kidney damage, review past history and previous measurements to determine duration of kidney disease. (Not Graded) • If duration is >3 months, CKD is confirmed. Follow
• We recommend that eGFRcreat should be reported and rounded to the nearest whole number and relative to a body surface area of 1.73 m 2 in adults using the units mL/ min/1.73 m 2 .
• We recommend eGFRcreat levels less than 60 mL/min/ 2 recommendations for CKD.
1.73 m should be reported as "decreased."
• If duration is not >3 months or unclear, CKD is not confirmed. Patients may have CKD or acute kidney diseases (including acute kidney injury [AKI]) or both, and tests should be repeated accordingly. • If eGFRcys/eGFRcreat-cys is also <60 mL/min/1.73 m 2 , the diagnosis of CKD is confirmed.
1.4.2: Evaluation
• If eGFRcys/eGFRcreat-cys is 2"60 mL/min/1.73 m 2 , the diagnosis of CKD is not confirmed.
: If cystatin C is measured, we suggest that health professionals (2C):
• use a GFR estimating equation to derive GFR from serum cystatin C rather than relying on the serum cystatin C concentration alone.
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• understand clinical settings in which eGFRcys and eGFRcreat-cys are less accurate.
:
We recommend that clinical laboratories that measure cystatin C should (1B):
• measure serum cystatin C using an assay with calibration traceable to the international standard reference material.
• report eGFR from serum cystatin C in addition to the serum cystatin C concentration in adults and specify the equation used whenever reporting eGFRcys and eGFRcreat-cys.
• report eGFRcys and eGFRcreat-cys in adults using the 2012 CKD-EPI cystatin C and 2012 CKD-EPI creatinine-cystatin C equations, respectively, or alternative cystatin Cbased GFR estimating equations if they have been shown to improve accuracy of GFR estimates compared with the 2012 CKD-EPI cystatin C and 2012 CKD-EPI creatininecystatin C equations.
When reporting serum cystatin C:
• We recommend reporting serum cystatin C concentration rounded to the nearest 100th of a whole number when expressed as conventional units (mg/L).
When reporting eGFRcys and eGFRcreat-cys:
• We recommend that eGFRcys and eGFRcreat-cys be reported and rounded to the nearest whole number and relative to a body surface area of 1.73 m 2 in adults using the units mL/min/1.73 m 2 .
• We recommend eGFRcys and eGFRcreat-cys levels less than 60 mL/min/1.73 m 2 should be reported as "decreased."
1.4.3.8 : We suggest measuring GFR using an exogenous filtration marker under circumstances where more accurate ascertainment of GFR will impact on treatment decisions. (2B) Evaluation of Albuminuria.
1.4.4.1 : We suggest using the following measurements for initial testing of proteinuria (in descending order of preference, in all cases an early morning urine sample is preferred (2B); 1) urine albumin-to-creatinine ratio (ACR); 2) urine protein-to-creatinine ratio (PCR); 3) reagent strip urinalysis for total protein with automated reading; 4) reagent strip urinalysis for total protein with manual reading; • Confirm reagent strip positive albuminuria and proteinuria by quantitative laboratory measurement and express as a ratio to creatinine wherever possible.
• Confirm ACR >30 mg/g (>3 mg/mmol) on a random untimed urine with a subsequent early morning urine sample.
• If a more accurate estimate of albuminuria or total proteinuria is required, measure albumin excretion rate or total protein excretion rate in a timed urine sample. 3.1.3 : Tailor BP treatment regimens in elderly patients with CKD by carefully considering age, comorbidities, and other therapies, with gradual escalation of treatment and close attention to adverse events related to BP treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension, and drug side effects. (Not Graded) 3.1.4 : We recommend that in both diabetic and nondiabetic adults with CKD and urine albumin excretion <30 mg/ 24 hours (or equivalent) whose office BP is consistently >140 mm Hg systolic or >90 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently S140 mm Hg systolic and S90 mm Hg diastolic. (1B) 3.1.5 : We suggest that in both diabetic and nondiabetic adults with CKD and with urine albumin excretion of 2"30 mg/24 hours (or equivalent) whose office BP is consistently >130 mm Hg systolic or >80 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently S130 mm Hg systolic and S80 mm Hg diastolic. (2D) 3.1.6: We suggest that an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACE-I) be used in diabetic adults with CKD and urine albumin excretion 30-300 mg/24 hours (or equivalent). (2D) 3.1.7: We recommend that an ARB or ACE-I be used in both diabetic and nondiabetic adults with CKD and urine albumin excretion >300 mg/24 hours (or equivalent). (1B) 3.1.8: There is insufficient evidence to recommend combining an ACE-I with ARBs to prevent progression of CKD. (Not Graded) 3.1.9: We recommend that in children with CKD, BPlowering treatment is started when BP is consistently above the 90th percentile for age, sex, and height. (1C) 3.1.10 : We suggest that in children with CKD (particu-larly those with proteinuria), BP is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypoten-sion. (2D) 3.1.11 : We suggest that an ARB or ACE-I be used in children with CKD in whom treatment with BPlowering drugs is indicated, irrespective of the level of proteinuria. (2D) CKD and risk of AKI 3.1.12 : We recommend that all people with CKD are considered to be at increased risk of AKI. (1A) 3.1.12.1: In people with CKD, the recommendations detailed in the KDIGO AKI Guideline should be followed for management of those at risk of AKI during intercurrent illness, or when undergoing investigation and procedures that are likely to increase the risk of AKI. (Not Graded) Protein intake 3.1.13 : We suggest lowering protein intake to 0.8 g/kg/d in adults with diabetes (2C) or without diabetes (2B) and GFR <30 mL/min/1.73 m 2 (GFR categories G4-G5), with appropriate education. • when clinically indicated in people with GFR 2"60 mL/ min/1.73 m 2 (GFR categories G1-G2); • at least annually in people with GFR 30e59 mL/min/1.73 m 2 (GFR categories G3a-G3b); • at least twice per year in people with GFR <30 mL/min/ 1.73 m 2 (GFR categories G4-G5). Referral to Specialist Services.
CKD
5.1.1 : We recommend referral to specialist kidney care services for people with CKD in the following circumstances (1B):
• AKI or abrupt sustained fall in GFR;
• GFR <30 mL/min/1.73 m 2 (GFR categories G4-G5) * ;
*If this is a stable isolated finding, formal referral (ie, formal consultation and ongoing care management) may not be necessary, and advice from specialist services may be all that is required to facilitate best care for the patients. This will be health-care system dependent.
• a consistent finding of significant albuminuria (ACR The comprehensive conservative management program should include protocols for symptom and pain management, psychological care, spiritual care, and culturally sensitive care for the dying patient and their family (whether at home, in a hospice or a hospital setting), followed by the provision of culturally appropriate bereavement support. (Not Graded) 
